|

Bicalutamide in combination with Sunitinib Clinical Trials

1 actively recruiting trial across 1 location

Also known as: (RS)-N-[4-cyano-3-(trifluoromethyl)phenyl]-3-[(4-fluorophenyl sulfonyl]-2-hydroxy-2-methylpropanamide, CASODEX, UNII: A0Z3NAU9DP

Pipeline

Phase 1/2: 1

Top Sponsors

  • State University of New York at Buffalo1

Indications

  • Carcinoma, Renal Cell1
  • Cancer1

Buffalo, New York1 trial

Study to Evaluate the Safety and Efficacy of Bicalutamide in Combination with Sunitinib in Patients with TKIs-resistant RCC

UB/ Great Lakes Cancer Care

Phase 1/2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.